OS Cancer Research Results

OS, overall survival: Click to Expand ⟱
Source:
Type:
Overall survival
GC, Gastric Adenocarcinoma: Click to Expand ⟱
Stomach/Gastric Cancer
Scientific Papers found: Click to Expand⟱
5581- B-Gluc,    Chemo-Immunotherapy Using Lentinan for the Treatment of Gastric Cancer with Liver Metastases
- Human, GC, NA
OS↑,
5576- B-Gluc,  Chemo,    Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy
- Trial, GC, NA
OS↑, eff↑,
5578- B-Gluc,    A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group
- Trial, GC, NA
OS↑, QoL↑,
5580- B-Gluc,    Lentinan, a Shiitake Mushroom β-Glucan, Downregulates the Enhanced PD-L1 Expression Induced by Platinum Compounds in Gastric Cancer Cells
- in-vitro, GC, MKN45
PD-L1↓, MAPK↓, OS↑, AntiTum↑, Imm↑,
217- MFrot,  MF,    Effect of low-frequency rotary magnetic fields on advanced gastric cancer
- in-vivo, GC, HL-60 - in-vivo, GC, SK-HEP-1
OS↑, Pain↓, ChemoSideEff↓, Weight↑, Strength↑, Sleep↑,
5286- Ramu,    Ramucirumab efficacy in first-line gastric and esophageal cancer treatment
- Review, GC, NA
VEGFR2↓, OS↑, toxicity↝,
5287- Ramu,    Real-Life Use of Ramucirumab in Gastric Cancer in Spain: the RAMIS Study
- in-vivo, GC, NA
VEGFR2↓, OS↑, OS↑,
5035- SAS,    Sulfasalazine, a potent suppressor of gastric cancer proliferation and metastasis by inhibition of xCT: Conventional drug in new use
- Human, GC, NA - in-vitro, GC, NCI-N87 - in-vitro, GC, SGC-7901
other?, TumCP↓, TumMeta↓, TumCI↓, xCT↓, OS↑,

Showing Research Papers: 1 to 8 of 8

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

xCT↓, 1,  

Cell Death ⓘ

MAPK↓, 1,  

Transcription & Epigenetics ⓘ

other?, 1,  

Migration ⓘ

TumCI↓, 1,   TumCP↓, 1,   TumMeta↓, 1,  

Angiogenesis & Vasculature ⓘ

VEGFR2↓, 2,  

Immune & Inflammatory Signaling ⓘ

Imm↑, 1,   PD-L1↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 1,  

Clinical Biomarkers ⓘ

PD-L1↓, 1,  

Functional Outcomes ⓘ

AntiTum↑, 1,   ChemoSideEff↓, 1,   OS↑, 9,   Pain↓, 1,   QoL↑, 1,   Sleep↑, 1,   Strength↑, 1,   toxicity↝, 1,   Weight↑, 1,  
Total Targets: 20

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: OS, overall survival
4 beta-glucans
2 Ramucirumab (CYRAMZA)
1 Chemotherapy
1 Magnetic Field Rotating
1 Magnetic Fields
1 Sulfasalazine
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:28  Cells:%  prod#:%  Target#:229  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page